Dechra has launched Cyclofin, an injectable single-dose solution for acute bovine respiratory disease (BRD) caused by oxytetracycline-sensitive Mannheimia (Pasteurella) haemolytica and Pasteurella multocida where an anti-inflammatory and anti-pyretic effect is needed.

Cyclofin contains two active ingredients: 200 mg/ml of the anti-inflammatory flunixin-meglumine (eq. to 33.2 mg/ml flunixin meglumine)  and 300 mg/ml of the class D anti-infective, oxytetracycline (eq. to 323.5 mg/ml oxytetracycline trihydrate).

Dechra says Cylofin acts within 24-36 hours and has sustained anti-bacterial activity for five to six days following a single intramuscular injection.

Administration is deep intramuscular injection in cattle and Cyclofin has a 35-day withdrawal period and a memorable dose rate of 1 ml per 10 kg body weight.

Alana McGlade MRCVS, national sales manager at Dechra, said: “BRD is one of the most prevalent and costly diseases on farm and early administration of an effective and fast-acting NSAID/antibiotic combination treatment, such as Cyclofin, can help relieve discomfort and stress, alleviate pain and improve demeanour and food intake.”

Cyclofin is available in 100ml vials.

https://www.dechra.co.uk/products/livestock/prescription/cyclofin#Cyclofin-300mg-ml.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.